RareMoon is in full preparation mode and enthusiastic about planning for a successful three days in San Francisco for the industry's biggest events of the year.
Why do we attend?
Considering what we've seen in the past few years, we are anticipating a lot of buzz around rare diseases, orphan drugs and novel therapies at the JP Morgan Healthcare Conference this upcoming January. For RareMoon, we consider JPM a time to tap into investors, bankers, and biotech companies investing both research efforts and time into the rare disease arena.
Read the full content at the original LinkedIn post.
Sabrina Mogle
CEO | Regulatory Strategist | Orphan Product Advisor
